^
    over2years
    Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Taiga Biotechnologies, Inc. | Phase classification: P1 --> P1/2 | N=20 --> 60 | Trial completion date: Apr 2022 --> Apr 2023 | Trial primary completion date: Jan 2022 --> Jan 2023
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD69 (CD69 Molecule)
    |
    TBX-3400